PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous sedative and anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

news

05/11/2016

Presentation Q1 2016

Presentation Q1 2016

Read more
05/11/2016

Quarterly statement for the first quarter 2016

Quarterly statement for the first quarter 2016

Read more
04/13/2016

Invitation including Agenda & Attendance

Invitation including Agenda & Attendance

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more

PAION Chart